Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 3/20 | 0.44 |
| ▸ | P2RX2 | Q9UBL9 | 3/20 | 0.44 |
| ▸ | BCL6 | P41182 | 2/20 | 0.43 |
| ▸ | ULK1 | O75385 | 1/20 | 0.41 |
| ▸ | TYRO3 | Q06418 | 4/20 | 0.40 |
| ▸ | FLT3 | P36888 | 3/20 | 0.40 |
| ▸ | MERTK | Q12866 | 3/20 | 0.40 |
| ▸ | GAS6 | Q14393 | 3/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.40 |
| ▸ | AXL | P30530 | 2/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
| ▸ | FLT1 | P17948 | 1/20 | 0.39 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.39 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.39 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.39 |
| ▸ | FLT4 | P35916 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15142272 | 0.91 | ULK1 (0.42) | P2RX3P2RX2BCL6ULK1TYRO3 | |
| SCHEMBL3455242 | 0.85 | ULK1 (0.41) | ULK1TYRO3FLT3MERTKGAS6 | |
| SCHEMBL21824038 | 0.81 | BCL6 (0.42) | P2RX3P2RX2BCL6TYRO3FLT3 | |
| SCHEMBL2068179 | 0.80 | ULK1 (0.45) | BCL6ULK1ADORA1ADORA2AKDR | |
| SCHEMBL21823999 | 0.74 | ADORA2A (0.46) | P2RX3P2RX2ULK1ADORA1ADORA2A | |
| SCHEMBL21823998 | 0.74 | ADORA2A (0.46) | P2RX3P2RX2ULK1ADORA1ADORA2A | |
| SCHEMBL15142751 | 0.74 | ULK1 (0.48) | P2RX3P2RX2ULK1ADORA1ADORA2A | |
| SCHEMBL20836481 | 0.73 | ULK1 (0.47) | ULK1ADORA1ADORA2AKDRLRRK2 | |
| SCHEMBL15509056 | 0.70 | GAA (0.47) | P2RX3P2RX2BCL6TYRO3FLT3 | |
| SCHEMBL16045208 | 0.70 | KDR (0.47) | BCL6ULK1ADORA1ADORA2AFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3632906-B1 | AZAARYL DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF FOR USE IN PHARMACY | ABBISKO THERAPEUTICS CO LTD (CN) | 2023-12-13 | — | — | EP | disclosed |
| EP-3632906-B1 | AZAARYL DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF FOR USE IN PHARMACY | ABBISKO THERAPEUTICS CO LTD (CN) | 2023-12-13 | — | — | EP | disclosed |
| WO-2023125812-A1 | SUBSTITUTED PYRIMIDONE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND MEDICAL USE THEREOF | 上海海雁医药科技有限公司 | 2023-07-06 | — | — | WO | disclosed |
| US-11130762-B2 | Azaaryl derivative, preparation method therefor, and application thereof for use in pharmacy | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2021-09-28 | — | — | US | disclosed |
| US-11130762-B2 | Azaaryl derivative, preparation method therefor, and application thereof for use in pharmacy | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2021-09-28 | — | — | US | disclosed |
| US-20200165254-A1 | AZAARYL DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF FOR USE IN PHARMACY | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2020-05-28 | — | — | US | disclosed |
| US-20200165254-A1 | AZAARYL DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF FOR USE IN PHARMACY | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2020-05-28 | — | — | US | disclosed |
| EP-3632906-A1 | AZAARYL DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF FOR USE IN PHARMACY | Abbisko Therapeutics Co., Ltd. (CN) | 2020-04-08 | — | — | EP | disclosed |
| EP-3632906-A1 | AZAARYL DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF FOR USE IN PHARMACY | Abbisko Therapeutics Co., Ltd. (CN) | 2020-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200165254-A1 | AZAARYL DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF FOR USE IN PHARMACY | FAR1, CSF1R, CSF3R | P2RX3 2498/4885P2RX2 2902/4885BCL6 1389/4885 |
| US-11130762-B2 | Azaaryl derivative, preparation method therefor, and application thereof for use in pharmacy | FAR1, CSF1R, CSF3R | P2RX3 2498/4885P2RX2 2902/4885BCL6 1389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.